Single-step nasal spray naloxone easiest to deliver according to new research

Single-step nasal spray naloxone is the easiest to deliver, according to new research led by faculty at Binghamton University, State University at New York.

Expanded access to naloxone, also known as Narcan, has been identified as a key intervention for reducing opioid-related deaths. However, there is more than one way to administer it and it is unknown which method is most successful when administered by community members.

William Eggleston, clinical assistant professor at the School of Pharmacy and Pharmaceutical Sciences at Binghamton University, was interested in knowing how successfully community members could administer naloxone after basic video training.

“I’m studying things like which type of naloxone should we give to members of the community, and what is the best way to distribute that naloxone,” Eggleston said.

In collaboration with SUNY Upstate Medical University in Syracuse, N.Y., Eggleston conducted a study to estimate and compare the rate of successful administration and the time to successful administration by community members for single-step nasal spray, multi-step atomized nasal spray and intramuscular simulated naloxone.

Over a three-day period at the New York State Fair in Syracuse, 138 adults with no prior naloxone training were asked to watch a two-minute video demonstrating how to administer naloxone via one of the three methods—two nasal sprays and one intramuscular—and then to administer the naloxone to a mannequin using their randomly selected method.

After the video training, participants were able to administer the single-step nasal spray naloxone with a higher rate of success than the intramuscular naloxone, and also to administer the single-step nasal spray naloxone more rapidly than either the multi-step atomized spray or the intramuscular naloxone. This information is important for community naloxone programs across the United States.

“With training, nasal sprays in general had a higher degree of success than the shot,” Eggleston said. “Even if it seemed to us it was a no-brainer that we should be using nasal sprays, we had no data before, so now we have some to support that.”

Source: Read Full Article